bioihbjkbjnl/mcl2 huggingface dataset:
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Condition: Psoriatic Arthritis
MeSH terms: Arthritis; Arthritis, Psoriatic
Intervention: Ixekizumab; Adalimumab
Intervention description: Administered SC; Administered SC
Intervention MeSH terms: Adalimumab; Ixekizumab
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 566.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab
      versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic
      disease-modifying anti-rheumatic drugs (DMARD) naive.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Presence of established diagnosis of active psoriatic arthritis for at least 6 months,
             and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria

          -  Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3
             (out of 66) swollen joints

          -  Presence of active plaque psoriasis with a BSA ≥3%

          -  Men must agree to use a reliable method of birth control or remain abstinent during
             the study

          -  Women must agree to use reliable birth control or remain abstinent during the study
             and for at least 12 weeks after stopping treatment

          -  Have had an inadequate response when treated with 1 or more conventional synthetic
             disease-modifying antirheumatic drugs (csDMARDs)

        Exclusion Criteria:

          -  Current or prior use of biologic agents for treatment of Ps or PsA

          -  Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other
             than PsA

          -  Have participated in any study with interleukin 17 (IL-17) antagonists, including
             ixekizumab

          -  Serious disorder or illness other than psoriatic arthritis

          -  Serious infection within the last 3 months

          -  Active Crohn's disease or active ulcerative colitis

          -  Active vasculitis or uveitis

          -  Diagnosis of or history of malignant disease <5 years prior to randomization

          -  Women who are breastfeeding
TXA vs. Amicar in Total Knee and Hip Arthroplasty
Condition: Blood Loss; Hip Arthritis; Knee Arthritis
MeSH terms: Arthritis
Intervention: Amicar; TXA
Intervention description: Subjects randomized to receive Amicar will receive this during surgical intervention; Subjects randomized to receive TXA will receive this during surgical intervention
Intervention MeSH terms: Tranexamic Acid; Aminocaproic Acid
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 246.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The purpose of this study is to determine the relative effectiveness of two drug agents,
      Tranexamic acid (TXA) and aminocaproic acid (Amicar), that act through a similar mechanism of
      action. These agents are used to decrease blood loss that is a result of major surgery, like
      total joint arthroplasty. A secondary goal will be investigate the cost-analysis of total
      hospitalization. Both TXA and Amicar are both currently used in the care of patients
      undergoing total joint arthroplasty.

      Subjects will be randomly assigned to the TXA or Amicar arm. All data needed for this study
      including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit
      and hemoglobin, and complications will be collected during the hospitalization stay.

      Our Hypothesis is that TXA and Amicar will have similar effectiveness in preventing
      intraoperative blood loss and the need for transfusion post-op than Amicar.

      A detailed cost analysis will show that the overall cost of performing the operative
      procedure, including transfusions, OR time, and total costs associated with admission cost
      will be more decreased with Amicar as compared to TXA.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients electing to undergo primary total hip or knee arthroplasty

        Exclusion Criteria:

          -  History of stents

          -  Myocardial infarction,

          -  Cerebrovascular accident or stroke

          -  Deep venous thrombus

          -  Pulmonary embolus

          -  Late onset color blindness

          -  Hypercoagulable state
Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture
Condition: Trigger Finger Disorder
MeSH terms: Trigger Finger Disorder
Intervention: Dexamethasone Sodium Phosphate; Xylocaine; Sodium Chloride
Intervention description: adreno-cortical steroid anti-inflammatory drug; a local anesthetic agent; Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
Intervention MeSH terms: Dexamethasone; Dexamethasone acetate; Lidocaine; Dexamethasone 21-phosphate; BB 1101
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 26.0
Sex: All
Minimum age: 18 Years
Maximum age: 90 Years
Healthy volunteers: No
Keywords: flexor tendon entrapment; snapping finger; trigger digits; trigger thumb

Summary:

      This research is being done to compare pain relief and efficacy of trigger finger injection
      using a combination of lidocaine/corticosteroid versus corticosteroid injection alone versus
      corticosteroid/saline combination.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-90

          -  Male or female (non-pregnant)

          -  Clinically diagnosed trigger digit

          -  Subject is able to provide voluntary, written informed consent

          -  Subject, in the opinion of the clinical investigator, is able to understand the
             clinical investigation and is willing to perform all study procedures and follow-up
             visits.

        Exclusion Criteria:

          -  Age <18 or >90

          -  Pregnant or lactating women

          -  Non-English speaking individuals

          -  Medication contradictions to lidocaine, corticosteroids and/or saline

          -  Prior injection or surgery on the affected finger

          -  Diagnosis of reflex symptomatic dystrophy (RSD) or complex regional pain syndrome
             (CRPS)

          -  Open wound
Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia
Condition: Hypoxia, Altitude
MeSH terms: Altitude Sickness; Hypoxia
Intervention: Cetirizine; Placebo oral capsule; Hypoxia
Intervention description: Cetirizine tablet 10 mg; Gelatin placebo; Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
Intervention MeSH terms: Cetirizine
Phase: Phase 4
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 13.0
Sex: All
Minimum age: 18 Years
Maximum age: 35 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec®
      use can improve exercise performance of active individuals when acutely exposed to altitude.
      For this project, healthy subjects will perform steady state and progressive work rate
      exercise, endurance performance time trials, and repeated sprint performance time trials in
      the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of
      Cetirizine or a placebo in a repeated measures design.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Physically active a minimum of 120 minutes a week, as determined by questionnaire

          -  18-35 years of age

          -  Classified as low risk, based on the modified PAR-Q questionnaire, BMI, and
             non-smoking status

          -  No history of pulmonary disease and pulmonary function classified as normal, as
             defined by the following measurements being 80% of predicted values: forced vital
             capacity (FVC), forced expired volume in one second (FEV1) and FEV1/FVC, according to
             the American Thoracic Society standards.

        Exclusion Criteria:

          -  Current smoker

          -  Women who are pregnant or could possibly be pregnant

          -  BMI > 25 kg/m2

          -  A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire

          -  History of pulmonary disease or <80% of predicted FCV, FEV1 and/or FEV1/FVC.

          -  A history of renal or liver disease, due to possible interaction effect with
             Cetirizine

          -  Currently taking any prescription or over the counter medications for the treatment of
             allergies, or taking any of the below listed drugs known to have a moderate or higher
             interaction effect with Cetirizine:

        isocarboxazid tranylcypromine bosutinib clobazam crizotinib daclatasvir eliglustat
        hyaluronidase lomitapide lurasidone ombitasvir/paritaprevir/ritonavir phenelzine ponatinib
        ritonavir vemurafenib
Comparison of Postoperative Delirium in Patients Anaesthetised With Isoflurane and Desflurane During Spinal Surgery
Condition: Postoperative Delirium
MeSH terms: Delirium; Emergence Delirium
Intervention: Isoflurane; Desflurane
Intervention MeSH terms: Desflurane; Isoflurane
Phase: Phase 4
Study type: Interventional
Primary purpose: Diagnostic
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 60.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No
Keywords: Postoperative delirium; spine surgery; isoflurane; desflurane

Summary:

      Postoperative delirium (POD) is a known complication of inhalational agents used to
      anaesthetise patients for surgery with potential long term implications.The incidence of
      postoperative delirium in spine surgery is 3.3% to 3.8%.The purpose of this study is to
      compare the occurrence of postoperative delirium with inhalational anaesthetics namely
      isoflurane and desflurane in spine surgery patients.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients scheduled for spine surgery.

          -  Age between 18-65 years

          -  American Society of Anaesthesiologists (ASA) Grade I and II patients

          -  Patients with Glasgow Coma Scale (GCS) of 15

          -  Postoperative Aldrette score > 9

        Exclusion Criteria:

          -  Cardiorespiratory disorders

          -  Associated cerebral disease

          -  Psychiatric illness

          -  Electrolyte and hormonal imbalance

          -  History of drug abuse

          -  Postoperative meningitis

          -  Administration of high dose steroids
Efficacy of Naproxen-codeine, Naproxen+Dexamethasone, and Naproxen on Myofascial Pain
Condition: Temporomandibular Disorder
MeSH terms: Temporomandibular Joint Disorders; Temporomandibular Joint Dysfunction Syndrome
Intervention: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
Intervention description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
Intervention MeSH terms: Acetaminophen; Dexamethasone; Naproxen; Codeine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 200.0
Sex: All
Minimum age: 18 Years
Maximum age: 69 Years
Healthy volunteers: No
Keywords: naproxen sodium; codeine phosphate; dexamethasone; pain; temporomandibular joint

Summary:

      Temporomandibular disorders (TMDs) are one of the most common muco-skeletal disorders, seen
      in the dental clinics. Many factors work together to initiate or aggravate the condition, so
      it is a multifactorial disorder. The etiology of TMDs may be a result of parafunctional
      habits such as clenching and bruxism, acute trauma to the jaw, trauma from hyperextension
      e.g. after a long dental treatment, joint laxity, psychological distress, occlusal disharmony
      like presence of high crown or free-end saddle leading to joint instability or systemic
      diseases such as Rheumatoid arthritis or Osteoarthritis. The aim of this study was to
      evaluate the effects of naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, and
      naproxen sodium on pain in patients complaining from temporomandibular pain.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Without a systemic disease,

          -  Not used any medication in the last week

          -  Have a habit of clenching and / or grinding teeth, individuals with normal
             preoperative results, suffering with pain and / or limitation of the mouth opening in
             the temporomandibular region

        Exclusion Criteria:

        Individuals who smoke

          -  Have a parafunctional habits (except for squeezing and grinding teeth)

          -  Pregnant and breastfeeding individuals

          -  Allergies to study medicines

          -  Do not use their medications / use different drugs and non-follow-up
Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Condition: Arteriovenous Fistula
MeSH terms: Arteriovenous Fistula; Fistula
Intervention: Topical Tranexamic Acid 5% with bacitracin; Topical Tranexamic Acid 25% with bacitracin
Intervention description: Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.; Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
Intervention MeSH terms: Bacitracin; Tranexamic Acid
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 17.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: hemodialysis; fistula; clotting; tranexamic acid; bacitracin

Summary:

      This study will investigate how the use of Tranexamic acid and Bacitracin applied to the
      bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and
      Infection Rate
    

Eligibility criteria:

        Inclusion Criteria:

          -  Dialysis patients with fistulas (native arterio-venous)

        Exclusion Criteria:

          -  Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.

          -  Active infection.

          -  Stenosis of fistula.
Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide
Condition: Hypertension
MeSH terms: Hypertension
Intervention: Nebivolol; Hydrochlorothiazide
Intervention description: Nebivolol 5mg then nebivolol 10 mg; Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
Intervention MeSH terms: Hydrochlorothiazide; Nebivolol
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Enrollment: 41.0
Sex: All
Minimum age: 30 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      Patients who have obstructive sleep apnea (OSA) frequently stop breathing while they sleep.
      They often develop high blood pressure. We are not sure what drug is best to treat the high
      blood pressure. This study will give the patients nebivolol or hydrochlorothiazide (HCTZ) for
      6 weeks after 2 weeks of placebo. The blood pressure response will be evaluated by 24 hour
      monitoring.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients ranging from 20 - 80 years

          -  Body mass index (BMI) of 20-38 to include the typical obese OSA patients

          -  Hypertension with blood pressures > 140/90 but less than 180/105 mmHg.

          -  Apnea-hypopnea index above 10

        Exclusion Criteria:

          -  Receiving sleep medicines (including heavy alcohol use) or drugs with adverse
             interactions with study medication.

          -  Women who have premenstrual syndrome, or those who are pregnant or capable of
             pregnancy and unwilling to use effective non-hormonal contraception

          -  Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in
             order to minimize confounding effects of other sleep disorders

          -  Have apneas which are primarily central

          -  Have sleep fragmentation caused by syndromes such as chronic pain or movement
             disorders

          -  Have diseases such as asthma or chronic obstructive pulmonary disease that compromises
             respiration.

          -  Have known coronary or cerebral vascular disease, history of arrhythmias,
             cardiomyopathy, history of psychosis, current alcohol or drug abuse.

          -  Have any contraindications to any study materials, such as heart block.

          -  Have secondary hypertension

          -  Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria
             or electrolyte disorders.
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Condition: Age-Related Macular Degeneration
MeSH terms: Macular Degeneration; Geographic Atrophy; Atrophy
Intervention: Ranibizumab 0.5 mg; Aflibercept 2.0 mg
Intervention description: Administered as an intravitreal injection; Administered as an intravitreal injection
Intervention MeSH terms: Ranibizumab; Aflibercept
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Masking description: Investigators were not masked. The patients, the BCVA assessors, and the Central Reading Center (who set the treatment intervals) were masked.
Enrollment: 281.0
Sex: All
Minimum age: 50 Years
Healthy volunteers: No
Keywords: Age-related macular degeneration; AMD; wet AMD; ranibizumab; aflibercept; geographic atrophy; inject and extend

Summary:

      The purpose of this study was to compare the development of new geographic atrophy in
      patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab
      or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result
      in the progressive and irreversible loss of visual function over time.
    

Eligibility criteria:

        Inclusion criteria:

        - Written informed consent.

        Inclusion criteria specific to the study eye:

          -  Diagnosis of active subfoveal Choroidal Neovascularisation (CNV) secondary to wet
             Age-related Macular Degeneration (AMD);

          -  Best Corrected Visual Acuity (BCVA) score of 23 letters or more as measured by 3-metre
             Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts.

        Exclusion criteria:

          -  Pregnant, nursing, or at risk of becoming pregnant during the study;

          -  Inability to comply with the study or follow-up procedures;

          -  Recent (3 months) stroke or myocardial infarction; uncontrolled hypertension;
             hypersensitivity to the study treatments or to fluorescein;

          -  In either eye: active periocular or ocular infection or inflammation; iris
             neovascularisation; uncontrolled or neovascular glaucoma; or one or more patch of
             geographic atrophy (GA) as specified in the protocol.

        Exclusion criteria specific to the study eye:

          -  Prior or current treatment with anti-angiogenic drugs or corticosteroids;

          -  Other eye conditions as specified in the protocol;

          -  Any intraocular procedure carried out within 2 months before baseline or anticipated
             within 6 months following baseline.
Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block
Condition: ACL Surgery
Intervention: ACB within true AC with bupivacaine 0.5% 20cc; ACB proximal to true AC with bupivacaine 0.5% 20cc
Intervention description: The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.; Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
Intervention MeSH terms: Bupivacaine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 69.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: No

Summary:

      This is a prospective, randomized, single blinded trial involving human subjects. The goal of
      this study is to determine an optimal location (proximal or distal) for the nerve block and
      whether it will make a difference in how much opioid the patient will receive during and
      after surgery. Ultrasound will identify the adductor canal and the proximal end of the
      adductor canal/apex of the femoral triangle to determine the location of the blocks.

      Their will be two randomized groups: 1. ACB within true AC with bupivacaine 0.5% 20cc2. ACB
      proximal to true AC with bupivacaine 0.5% 20cc
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing unilateral, ACL surgery with allograft.

          -  Patients who consent to be randomized.

          -  Patients must be English proficient.

        Exclusion Criteria:

          -  Patients younger than 18 or older than 75 years of age;

          -  Patients with a history of chronic pain or who are taking medications intended to
             treat chronic pain such as strong opioids;

          -  Patients with history of neurologic disorder that can interfere with pain sensation;

          -  Patients with a history of drug or alcohol abuse;

          -  Patients who are unable to understand or follow instructions;

          -  Patients with an allergy or a contraindication to any of the medications used in the
             study, or patients with a contraindication to any of the study procedures;

          -  Patients with severe liver disease, renal insufficiency, congestive heart failure,
             and/ or significant heart disease;

          -  Patients with a BMI over 42;

          -  Any patient that the investigators feel cannot comply with all study related
             procedures.

          -  Patients who do not tolerate Percocet.